DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT02930265

UnknownPhase NA

Clinical Study of Liraglutide in Improving Cardiac Function for Patients With Ischemic Cardiomyopathy

Chinese People's Liberation Army General Hospital

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

400

estimated

Study population

Cardiovascular disease, Heart failure

Key I/E criterion

•EF ≤40%

Primary endpoint

•Expanded / custom MACE composite (Myocardial infarction (any), Non-fatal stroke, Coronary revascularization, Unstable angina hospitalization)

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT02930265
Org study IDqs20160920

Timeline

Milestones

Study first posted2016-10-12estimated
Last update posted2016-10-12estimated
Study start2016-09 (month precision)
Primary completion2018-02estimated (month precision)
Study completion2018-03estimated (month precision)

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Cardiovascular diseaseHeart failure

Eligibility

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Patients With Ischemic Cardiomyopathy: The clinical manifestations of heart failure (NYHA class II-IV grade), evidence of cardiac dysfunction (LVEF ≤40%, and LVEDD ≥55mm) and previous coronary angiography showed one or more severe coronary artery stenosis.

Exclusion criteria

•Valvular heart disease
•dilated cardiomyopathy
•patients requiring emergency PCI
•patients with cardiogenic shock;
•there have been recent acute myocardial infarction in one month;
•there have been recent acute stroke in one month;
•estimated glomerular filtration over rate eGFR <30ml / min / 1.73m2 (according to MDRD formula);
•malignant tumor
•severe liver failure
•respiratory failure

Endpoints (5)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Heart failure
4
Cardiovascular outcomes
1

Cardiovascular outcomes

1 endpoint
Primary/protocol endpoint

main adverse cardiovascular events

Time frame:Followed up for 6 months after enrolled in the study

Expanded / custom MACE composite

composite event, event

componentsMyocardial infarction (any), Non-fatal stroke, Coronary revascularization, Unstable angina hospitalization, All-cause death, Heart-failure hospitalization

Heart failure

4 endpoints
Secondary/protocol endpoint

New York Heart Association functional class

Time frame:Followed up for 6 months after enrolled in the study

NYHA class, change

categorical status, improvement

Secondary/protocol endpoint

left ventricular ejection fraction

Time frame:Followed up for 6 months after enrolled in the study

descriptive

Secondary/protocol endpoint

6-minute walk test

Time frame:Followed up for 6 months after enrolled in the study

6-minute walk distance

change from baseline, improvement

Secondary/protocol endpoint

KCCQ (Kansas City cardiomyopathy questionnaire) clinical total score

Time frame:Followed up for 6 months after enrolled in the study

KCCQ total score

change from baseline, improvement

Publications (15)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.